Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure

Milton Packer, Wilson Colucci, Lloyd Fisher, Barry M. Massie, John R. Teerlink, James Young, Robert J. Padley, Roopal Thakkar, Leticia Delgado-Herrera, Jeffrey Salon, Chris Garratt, Bidan Huang, Toni Sarapohja

Research output: Contribution to journalArticle

234 Citations (Scopus)

Abstract

Background: This study evaluated the efficacy and safety of levosimendan, a positive inotropic drug with vasodilator effects, given intravenously to patients with acutely decompensated heart failure (ADHF). Methods: We performed 2 sequential trials, the first to develop a new measure of efficacy in 100 patients, and the second to use this measure to evaluate levosimendan in an additional 600 patients. Patients admitted with ADHF received placebo or intravenous levosimendan for 24 h in addition to standard treatment. The primary endpoint was a composite that evaluated changes in clinical status during the first 5 days after randomization. Results: In the 600-patient trial, more levosimendan than placebo patients (58 vs. 44) were improved at all 3 pre-specified time points (6 h, 24 h, and 5 days), whereas fewer levosimendan patients (58 vs. 82) experienced clinical worsening (p = 0.015 for the difference between the groups). These differences were apparent, despite more frequent intensification of adjunctive therapy in the placebo group (79 vs. 45 patients). Improvements in patient self-assessment and declines in B-type natriuretic peptide levels with levosimendan persisted for 5 days and were associated with reduced length of stay (p = 0.009). Similar findings were present in the 100-patient pilot trial. Levosimendan was associated with more frequent hypotension and cardiac arrhythmias during the infusion period and a numerically higher risk of death across the 2 trials (49 of 350 on a regimen of levosimendan vs. 40 of 350 on a regimen of placebo at 90 days, p = 0.29). Conclusions: In patients with ADHF, intravenous levosimendan provided rapid and durable symptomatic relief. As dosed in this trial, levosimendan was associated with an increased risk of adverse cardiovascular events. (Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure; NCT00048425).

Original languageEnglish (US)
Pages (from-to)103-111
Number of pages9
JournalJACC: Heart Failure
Volume1
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Curriculum
Heart Failure
Placebos
simendan
Brain Natriuretic Peptide
Random Allocation
Vasodilator Agents
Hypotension
Cardiac Arrhythmias
Length of Stay
Therapeutics
Safety

Keywords

  • Heart failure
  • Inotropic agents
  • Trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Packer, M., Colucci, W., Fisher, L., Massie, B. M., Teerlink, J. R., Young, J., ... Sarapohja, T. (2013). Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC: Heart Failure, 1(2), 103-111. https://doi.org/10.1016/j.jchf.2012.12.004

Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. / Packer, Milton; Colucci, Wilson; Fisher, Lloyd; Massie, Barry M.; Teerlink, John R.; Young, James; Padley, Robert J.; Thakkar, Roopal; Delgado-Herrera, Leticia; Salon, Jeffrey; Garratt, Chris; Huang, Bidan; Sarapohja, Toni.

In: JACC: Heart Failure, Vol. 1, No. 2, 04.2013, p. 103-111.

Research output: Contribution to journalArticle

Packer, M, Colucci, W, Fisher, L, Massie, BM, Teerlink, JR, Young, J, Padley, RJ, Thakkar, R, Delgado-Herrera, L, Salon, J, Garratt, C, Huang, B & Sarapohja, T 2013, 'Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure', JACC: Heart Failure, vol. 1, no. 2, pp. 103-111. https://doi.org/10.1016/j.jchf.2012.12.004
Packer, Milton ; Colucci, Wilson ; Fisher, Lloyd ; Massie, Barry M. ; Teerlink, John R. ; Young, James ; Padley, Robert J. ; Thakkar, Roopal ; Delgado-Herrera, Leticia ; Salon, Jeffrey ; Garratt, Chris ; Huang, Bidan ; Sarapohja, Toni. / Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. In: JACC: Heart Failure. 2013 ; Vol. 1, No. 2. pp. 103-111.
@article{664b7605cfe24819b83d923c067bf87a,
title = "Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure",
abstract = "Background: This study evaluated the efficacy and safety of levosimendan, a positive inotropic drug with vasodilator effects, given intravenously to patients with acutely decompensated heart failure (ADHF). Methods: We performed 2 sequential trials, the first to develop a new measure of efficacy in 100 patients, and the second to use this measure to evaluate levosimendan in an additional 600 patients. Patients admitted with ADHF received placebo or intravenous levosimendan for 24 h in addition to standard treatment. The primary endpoint was a composite that evaluated changes in clinical status during the first 5 days after randomization. Results: In the 600-patient trial, more levosimendan than placebo patients (58 vs. 44) were improved at all 3 pre-specified time points (6 h, 24 h, and 5 days), whereas fewer levosimendan patients (58 vs. 82) experienced clinical worsening (p = 0.015 for the difference between the groups). These differences were apparent, despite more frequent intensification of adjunctive therapy in the placebo group (79 vs. 45 patients). Improvements in patient self-assessment and declines in B-type natriuretic peptide levels with levosimendan persisted for 5 days and were associated with reduced length of stay (p = 0.009). Similar findings were present in the 100-patient pilot trial. Levosimendan was associated with more frequent hypotension and cardiac arrhythmias during the infusion period and a numerically higher risk of death across the 2 trials (49 of 350 on a regimen of levosimendan vs. 40 of 350 on a regimen of placebo at 90 days, p = 0.29). Conclusions: In patients with ADHF, intravenous levosimendan provided rapid and durable symptomatic relief. As dosed in this trial, levosimendan was associated with an increased risk of adverse cardiovascular events. (Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure; NCT00048425).",
keywords = "Heart failure, Inotropic agents, Trials",
author = "Milton Packer and Wilson Colucci and Lloyd Fisher and Massie, {Barry M.} and Teerlink, {John R.} and James Young and Padley, {Robert J.} and Roopal Thakkar and Leticia Delgado-Herrera and Jeffrey Salon and Chris Garratt and Bidan Huang and Toni Sarapohja",
year = "2013",
month = "4",
doi = "10.1016/j.jchf.2012.12.004",
language = "English (US)",
volume = "1",
pages = "103--111",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure

AU - Packer, Milton

AU - Colucci, Wilson

AU - Fisher, Lloyd

AU - Massie, Barry M.

AU - Teerlink, John R.

AU - Young, James

AU - Padley, Robert J.

AU - Thakkar, Roopal

AU - Delgado-Herrera, Leticia

AU - Salon, Jeffrey

AU - Garratt, Chris

AU - Huang, Bidan

AU - Sarapohja, Toni

PY - 2013/4

Y1 - 2013/4

N2 - Background: This study evaluated the efficacy and safety of levosimendan, a positive inotropic drug with vasodilator effects, given intravenously to patients with acutely decompensated heart failure (ADHF). Methods: We performed 2 sequential trials, the first to develop a new measure of efficacy in 100 patients, and the second to use this measure to evaluate levosimendan in an additional 600 patients. Patients admitted with ADHF received placebo or intravenous levosimendan for 24 h in addition to standard treatment. The primary endpoint was a composite that evaluated changes in clinical status during the first 5 days after randomization. Results: In the 600-patient trial, more levosimendan than placebo patients (58 vs. 44) were improved at all 3 pre-specified time points (6 h, 24 h, and 5 days), whereas fewer levosimendan patients (58 vs. 82) experienced clinical worsening (p = 0.015 for the difference between the groups). These differences were apparent, despite more frequent intensification of adjunctive therapy in the placebo group (79 vs. 45 patients). Improvements in patient self-assessment and declines in B-type natriuretic peptide levels with levosimendan persisted for 5 days and were associated with reduced length of stay (p = 0.009). Similar findings were present in the 100-patient pilot trial. Levosimendan was associated with more frequent hypotension and cardiac arrhythmias during the infusion period and a numerically higher risk of death across the 2 trials (49 of 350 on a regimen of levosimendan vs. 40 of 350 on a regimen of placebo at 90 days, p = 0.29). Conclusions: In patients with ADHF, intravenous levosimendan provided rapid and durable symptomatic relief. As dosed in this trial, levosimendan was associated with an increased risk of adverse cardiovascular events. (Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure; NCT00048425).

AB - Background: This study evaluated the efficacy and safety of levosimendan, a positive inotropic drug with vasodilator effects, given intravenously to patients with acutely decompensated heart failure (ADHF). Methods: We performed 2 sequential trials, the first to develop a new measure of efficacy in 100 patients, and the second to use this measure to evaluate levosimendan in an additional 600 patients. Patients admitted with ADHF received placebo or intravenous levosimendan for 24 h in addition to standard treatment. The primary endpoint was a composite that evaluated changes in clinical status during the first 5 days after randomization. Results: In the 600-patient trial, more levosimendan than placebo patients (58 vs. 44) were improved at all 3 pre-specified time points (6 h, 24 h, and 5 days), whereas fewer levosimendan patients (58 vs. 82) experienced clinical worsening (p = 0.015 for the difference between the groups). These differences were apparent, despite more frequent intensification of adjunctive therapy in the placebo group (79 vs. 45 patients). Improvements in patient self-assessment and declines in B-type natriuretic peptide levels with levosimendan persisted for 5 days and were associated with reduced length of stay (p = 0.009). Similar findings were present in the 100-patient pilot trial. Levosimendan was associated with more frequent hypotension and cardiac arrhythmias during the infusion period and a numerically higher risk of death across the 2 trials (49 of 350 on a regimen of levosimendan vs. 40 of 350 on a regimen of placebo at 90 days, p = 0.29). Conclusions: In patients with ADHF, intravenous levosimendan provided rapid and durable symptomatic relief. As dosed in this trial, levosimendan was associated with an increased risk of adverse cardiovascular events. (Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure; NCT00048425).

KW - Heart failure

KW - Inotropic agents

KW - Trials

UR - http://www.scopus.com/inward/record.url?scp=84877960102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877960102&partnerID=8YFLogxK

U2 - 10.1016/j.jchf.2012.12.004

DO - 10.1016/j.jchf.2012.12.004

M3 - Article

C2 - 24621834

AN - SCOPUS:84877960102

VL - 1

SP - 103

EP - 111

JO - JACC: Heart Failure

JF - JACC: Heart Failure

SN - 2213-1779

IS - 2

ER -